ELITE PHARMACEUTICALS INC /NV/ Quarterly Accrued Liabilities, Current in USD from Q1 2015 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly Accrued Liabilities, Current history and growth rate from Q1 2015 to Q4 2024.
  • Elite Pharmaceuticals Inc /Nv/ Accrued Liabilities, Current for the quarter ending December 31, 2024 was $3.72M, a 68.7% decline year-over-year.
Accrued Liabilities, Current, Quarterly (USD)
Accrued Liabilities, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 $3.72M -$8.17M -68.7% Dec 31, 2024 10-Q 2025-02-13
Q3 2024 $5.7M -$5.45M -48.9% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $6.23M +$299K +5.04% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $5.3M +$254K +5.03% Mar 31, 2024 10-Q 2025-02-13
Q4 2023 $11.9M +$7.21M +154% Dec 31, 2023 10-Q 2024-02-14
Q3 2023 $11.2M +$6.58M +144% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $5.93M +$1.12M +23.3% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $5.05M +$355K +7.56% Mar 31, 2023 10-K 2024-07-01
Q4 2022 $4.68M +$650K +16.1% Dec 31, 2022 10-Q 2023-02-14
Q3 2022 $4.58M +$799K +21.1% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $4.81M +$869K +22% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $4.69M +$423K +9.89% Mar 31, 2022 10-K 2023-06-29
Q4 2021 $4.03M -$579K -12.6% Dec 31, 2021 10-Q 2022-02-14
Q3 2021 $3.78M -$730K -16.2% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 $3.94M -$624K -13.7% Jun 30, 2021 10-Q 2021-08-16
Q1 2021 $4.27M -$551K -11.4% Mar 31, 2021 10-K 2022-06-29
Q4 2020 $4.61M +$181K +4.1% Dec 31, 2020 10-Q 2021-02-16
Q3 2020 $4.51M +$457K +11.3% Sep 30, 2020 10-Q 2020-11-16
Q2 2020 $4.56M +$930K +25.6% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 $4.82M +$1.11M +29.8% Mar 31, 2020 10-K 2021-06-14
Q4 2019 $4.42M +$1.39M +45.9% Dec 31, 2019 10-Q 2020-02-10
Q3 2019 $4.05M +$1.39M +52.2% Sep 30, 2019 10-Q 2019-11-12
Q2 2019 $3.63M +$1.66M +84.5% Jun 30, 2019 10-Q 2019-08-09
Q1 2019 $3.71M +$1.93M +108% Mar 31, 2019 10-K 2020-06-30
Q4 2018 $3.03M +$1.25M +69.8% Dec 31, 2018 10-Q 2019-02-11
Q3 2018 $2.66M +$1.33M +99.2% Sep 30, 2018 10-Q 2018-11-09
Q2 2018 $1.97M +$768K +63.9% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 $1.79M +$994K +125% Mar 31, 2018 10-K 2019-06-21
Q4 2017 $1.79M -$16.9K -0.94% Dec 31, 2017 10-Q 2018-02-09
Q3 2017 $1.34M -$93.2K -6.52% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 $1.2M -$195K -14% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 $795K +$239K +43.1% Mar 31, 2017 10-K 2018-06-14
Q4 2016 $1.8M Dec 31, 2016 10-Q 2017-02-09
Q3 2016 $1.43M Sep 30, 2016 10-Q 2016-11-09
Q2 2016 $1.4M Jun 30, 2016 10-Q 2016-08-09
Q1 2016 $555K -$58.6K -9.55% Mar 31, 2016 10-K 2017-06-14
Q1 2015 $614K Mar 31, 2015 10-K 2016-06-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.